XM اپنی سروسز امریکہ کے شہریوں کو فراہم نہیں کرتا ہے۔

I
I

IQVIA

خبر

Reuters - 2 ہفتے پہلے

India's Strides Pharma at near 2-year high on FDA nod for Dolutegravir

BUZZ-India's Strides Pharma at near 2-year high on FDA nod for Dolutegravir ** Shares of Strides Pharma Science SRID.NS rise as much as 11.7% to 522.75 rupees, their highest level since Nov. 26, 2021 ** The pharma co's Singapore unit got tentative approval for Dolutegravir 50mg tablets from the U.S. Food & Drug Administration ** The HIV treatment drug complements co’s approved range of first-line HIV treatments ** Dolutegravir 50mg tablet has market opportunity in the U.S.
I
Reuters - 3 ہفتے پہلے

U.S. Associated Banc-Corp, Celanese Corporation, Hess

U.S. RESEARCH ROUNDUP-Associated Banc-Corp, Celanese Corporation, Hess Sept 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Associated Banc-Corp, Celanese Corporation and Hess on Wednesday. HIGHLIGHTS * Associated Banc-Corp ASB.N : Baird raises to outperform * Celanese Corporation CE.N : Keybanc raises to overweight from sector weight * Constellation Brands Inc STZ.N : TD Cowen raises to outperform from market perf
A
A
B
C
D
E
G
S
E
A
C
E
I
L
Reuters - 1 مہینے پہلے

What happens when a $2 million gene therapy is not enough

CORRECTED-INSIGHT-What happens when a $2 million gene therapy is not enough Corrects paragraph 27: ICER's final analysis was that Zolgensma was cost effective at a price of $1.1 million to $1.9 million. Zolgensma launched as possible "cure," now outcomes paint nuanced picture Positive results, but add-on therapies increasing, neurologists say Once world's priciest drug, that raises questions for other gene therapies By Deena Beasley LOS ANGELES, Aug 16 (Reuters) - Baby Ben Kutschke was diagnosed
B
N
R
I
Reuters - 2 مہینے پہلے

What happens when a $2 million gene therapy is not enough

INSIGHT-What happens when a $2 million gene therapy is not enough Zolgensma launched as possible "cure," now outcomes paint nuanced picture Positive results, but add-on therapies increasing, neurologists say Once world's priciest drug, that raises questions for other gene therapies By Deena Beasley LOS ANGELES, Aug 12 (Reuters) - Baby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.
B
N
R
I
Reuters - 2 مہینے پہلے

Biocon may list biosimilars business by 2025 first half - CEO

Biocon may list biosimilars business by 2025 first half - CEO By Rishika Sadam HYDERABAD, Aug 11 (Reuters) - Indian biopharmaceutical company Biocon Ltd BION.NS is planning to list its biosimilars business, a significant contributor to the company's total revenue, by the first half of 2025, a top executive said on Friday. Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe.
I
Reuters - 2 مہینے پہلے

U.S. STOCKS Marriott, Advanced Micro Devices, Leidos Holdings

BUZZ-U.S. STOCKS ON THE MOVE-Marriott, Advanced Micro Devices, Leidos Holdings Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell on Tuesday as investors assessed mixed earnings from industry heavyweights and digested data that showed manufacturing activity slowed more than expected in July.
A
I
J
M
P
S
U
U
E
G
I
U
A
I
L
M
Reuters - 2 مہینے پہلے

U.S. STOCKS SiriusXM, ABVC Biopharma, Altria

BUZZ-U.S. STOCKS ON THE MOVE-SiriusXM, ABVC Biopharma, Altria Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was set to open lower on Tuesday ahead of economic data that could clear the air on a soft landing for the U.S. economy, while investors assessed mixed earnings from pharmaceutical heavyweights Merck and Pfizer.
A
I
J
P
S
U
U
E
G
I
U
A
I
L
M
Reuters - 2 مہینے پہلے

IQVIA falls on forecast cuts due to soft demand for healthcare tech services

BUZZ-IQVIA falls on forecast cuts due to soft demand for healthcare tech services ** Shares of contract research firm IQVIA Holdings IQV.N down 2.5% at $218.20 ** Co cuts FY profit, rev forecasts as it expects slower demand from clients for in its healthcare data and analytics services ** It sees FY adj. profit of between $10.20/share and $10.45/sh
I
Reuters - 2 مہینے پہلے

IQVIA Holdings Inc reports results for the quarter ended in June - Earnings Summary

IQVIA Holdings Inc reports results for the quarter ended in June - Earnings Summary IQVIA Holdings Inc IQV.N reported quarterly adjusted earnings of $2.43​​ per share for the quarter ended in June. The mean expectation of twenty two analysts for the quarter was for earnings of $2.37 per share. Revenue rose 5.3% to $3.73 billion from a year ago; analysts expected $3.71 billion.
I
Reuters - 2 مہینے پہلے

IQVIA cuts annual profit forecast on soft demand for healthcare tech services

IQVIA cuts annual profit forecast on soft demand for healthcare tech services Aug 1 (Reuters) - Contract research firm IQVIA Holdings IQV.N cut its annual profit and revenue forecasts on Tuesday, on expectations of slower demand from clients for its healthcare data and analytics services. Its Technology & Analytics Solutions unit, IQVIA's second largest, through which it provides services such as information on drug prescription trends and data and tech-based services for drug trials, brought in
I
Reuters - 2 مہینے پہلے

IQVIA Q2 Adjusted EPS USD 2.43 Vs. IBES Estimate USD 2.37

Aug 01 (Reuters) - IQVIA Q2 revenue USD 3,728 million vs. IBES estimate USD 3,709 million. Q2 net income USD 297 million Q2 adjusted EBITDA USD 864 million Q2 EPS USD 1.59 Outlook Q3 Revenue USD 3,760-3,810 Million Outlook Q3 Revenue Growth 5.6-7%
I
Reuters - 2 مہینے پہلے

August cools Wall St stocks

MORNING BID AMERICAS-August cools Wall St stocks . A look at the day ahead in U.S. and global markets from Mike Dolan After notching a fifth straight month of gains for July .SPX , Wall St stocks looked set to step back on Tuesday as a deluge of corporate earnings hit this week and poor manufacturing soundings from around the world set a more edgy backdrop.
A
G
H
I
M
M
P
S
A
E
J
U
U
E
I
L
P
U
Z
A
H
I
L
M
P
S
Reuters - 2 مہینے پہلے

What to Watch in the Day Ahead - Tuesday, Aug. 1

What to Watch in the Day Ahead - Tuesday, Aug. 1 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT On the U.S. economic calendar, the Institute for Supply Management (ISM) is expected to report manufacturing PMI likely rose to 46.8 in July from 46.0 in the previous month.
J
M
P
S
V
A
A
E
P
U
G
I
S
Reuters - 2 مہینے پہلے

IQVIA Holdings Inc expected to post earnings of $2.37 a share - Earnings Preview

IQVIA Holdings Inc expected to post earnings of $2.37 a share - Earnings Preview IQVIA Holdings Inc IQV.N , IQV is expected to show a rise in quarterly revenue when it reports results on August 1. The Durham North Carolina-based company is expected to report a 4.7% increase in revenue to $3.709 billion from $3.54 billion a year ago, according to the mean estimate from 17 analysts, based on Refinitiv data.
I
Reuters - 2 مہینے پہلے

TPG to buy healthcare IT platform Nextech for $1.4 bln

UPDATE 2-TPG to buy healthcare IT platform Nextech for $1.4 bln Adds background in paragraphs 2-5 July 19 (Reuters) - TPG Inc TPG.O said on Wednesday it has agreed to buy healthcare IT platform Nextech for $1.4 billion to increase the private equity firm's presence in the healthcare services market. The deal gives TPG access to Nextech's network of over 11,000 physicians and more than 60,000 clinics, to which it provides services.
I
Reuters - 2 مہینے پہلے

US FTC Says It Seeks to Block IQVIA's Acquisition of Propel Media

BRIEF-US FTC Says It Seeks to Block IQVIA's Acquisition of Propel Media July 17 (Reuters) - U.S. FTC SAYS IT SUES TO BLOCK IQVIA’S ACQUISITION OF PROPEL MEDIA TO PREVENT INCREASED CONCENTRATION IN HEALTH CARE PROGRAMMATIC ADVERTISING U.S. FTC SAYS IT SUES TO BLOCK IQVIA’S ACQUISITION OF PROPEL MEDIA TO PREVENT INCREASED CONCENTRATION IN HEALTH
I
Reuters - 4 مہینے پہلے

Iqvia Announces Pricing Of Upsized Offering Of Senior Secured Notes And Senior Notes

BRIEF-Iqvia Announces Pricing Of Upsized Offering Of Senior Secured Notes And Senior Notes IQVIA Holdings Inc IQV.N : IQVIA ANNOUNCES PRICING OF UPSIZED OFFERING OF SENIOR SECURED NOTES AND SENIOR NOTES IQVIA HOLDINGS INC: SUBSIDIARY PRICED AN OFFERING OF $1.25 BILLION IN AGGREGATE PRINCIPAL AMOUNT OF SENIOR NOTES Source text for Eikon: ID:nBw4NJdQ
I
Reuters - 4 مہینے پہلے

IQVIA Announces Offering Of Senior Secured Notes And Senior Notes

BRIEF-IQVIA Announces Offering Of Senior Secured Notes And Senior Notes May 18 (Reuters) - IQVIA Holdings Inc IQV.N : IQVIA ANNOUNCES OFFERING OF SENIOR SECURED NOTES AND SENIOR NOTES IQVIA HOLDINGS INC - UNIT INTENDS TO RAISE $1 BILLION THROUGH OFFERING OF SENIOR SECURED NOTES DUE 2028 AND SENIOR NOTES DUE 2030 Source text for Eikon: ID:nBw2XDrzGa
I
Reuters - 5 مہینے پہلے

Iqvia Reports First-Quarter 2023 Results Reaffirms Full-Year 2023 Guidance

BRIEF-Iqvia Reports First-Quarter 2023 Results Reaffirms Full-Year 2023 Guidance April 27 (Reuters) - IQVIA Holdings Inc IQV.N : IQVIA REPORTS FIRST-QUARTER 2023 RESULTS; REAFFIRMS FULL-YEAR 2023 GUIDANCE IQVIA HOLDINGS INC SAYS REAFFIRMS FULL-YEAR 2023 GUIDANCE Source text for Eikon: ID:nBwb28JGxa Further company coverage: IQV.N Reporting by Sidda
I
Reuters - 5 مہینے پہلے

One drug medication abortion with misoprostol grows in US

One drug medication abortion with misoprostol grows in US By Ahmed Aboulenein and Michael Erman WASHINGTON, April 20 (Reuters) - Use of the drug misoprostol on its own to terminate pregnancies is on the rise in the United States as providers seek a preemptive alternative while a ban on abortion pill mifepristone is being considered in court. Misoprostol is already part of the only medication abortion protocol approved by the U.S.
B
P
I

شرائط

مشہور اثاثے

دستبرداری: XM Group کے ادارے ہماری آن لائن تجارت کی سہولت تک صرف عملدرآمد کی خدمت اور رسائی مہیا کرتے ہیں، کسی شخص کو ویب سائٹ پر یا اس کے ذریعے دستیاب کانٹینٹ کو دیکھنے اور/یا استعمال کرنے کی اجازت دیتا ہے، اس پر تبدیل یا توسیع کا ارادہ نہیں ہے ، اور نہ ہی یہ تبدیل ہوتا ہے یا اس پر وسعت کریں۔ اس طرح کی رسائی اور استعمال ہمیشہ مشروط ہوتا ہے: (i) شرائط و ضوابط؛ (ii) خطرہ انتباہات؛ اور (iii) مکمل دستبرداری۔ لہذا اس طرح کے مواد کو عام معلومات سے زیادہ کے طور پر فراہم کیا جاتا ہے۔ خاص طور پر، براہ کرم آگاہ رہیں کہ ہماری آن لائن تجارت کی سہولت کے مندرجات نہ تو کوئی درخواست ہے، اور نہ ہی فنانشل مارکیٹ میں کوئی لین دین داخل کرنے کی پیش کش ہے۔ کسی بھی فنانشل مارکیٹ میں تجارت میں آپ کے سرمائے کے لئے ایک خاص سطح کا خطرہ ہوتا ہے۔

ہماری آن لائن تجارتی سہولت پر شائع ہونے والے تمام مٹیریل کا مقصد صرف تعلیمی/معلوماتی مقاصد کے لئے ہے، اور اس میں شامل نہیں ہے — اور نہ ہی اسے فنانشل، سرمایہ کاری ٹیکس یا تجارتی مشورے اور سفارشات؛ یا ہماری تجارتی قیمتوں کا ریکارڈ؛ یا کسی بھی فنانشل انسٹرومنٹ میں لین دین کی پیشکش؛ یا اسکے لئے مانگ؛ یا غیر متنازعہ مالی تشہیرات پر مشتمل سمجھا جانا چاہئے۔

کوئی تھرڈ پارٹی کانٹینٹ، نیز XM کے ذریعہ تیار کردہ کانٹینٹ، جیسے: راۓ، خبریں، تحقیق، تجزیہ، قیمتیں اور دیگر معلومات یا اس ویب سائٹ پر مشتمل تھرڈ پارٹی کے سائٹس کے لنکس کو "جیسے ہے" کی بنیاد پر فراہم کیا جاتا ہے، عام مارکیٹ کی تفسیر کے طور پر، اور سرمایہ کاری کے مشورے کو تشکیل نہ دیں۔ اس حد تک کہ کسی بھی کانٹینٹ کو سرمایہ کاری کی تحقیقات کے طور پر سمجھا جاتا ہے، آپ کو نوٹ کرنا اور قبول کرنا ہوگا کہ یہ کانٹینٹ سرمایہ کاری کی تحقیق کی آزادی کو فروغ دینے کے لئے ڈیزائن کردہ قانونی تقاضوں کے مطابق نہیں ہے اور تیار نہیں کیا گیا ہے، اسی طرح، اس پر غور کیا جائے گا بطور متعلقہ قوانین اور ضوابط کے تحت مارکیٹنگ مواصلات۔ براہ کرم یقینی بنائیں کہ آپ غیر آزاد سرمایہ کاری سے متعلق ہماری اطلاع کو پڑھ اور سمجھ چکے ہیں۔ مذکورہ بالا معلومات کے بارے میں تحقیق اور رسک وارننگ ، جس تک رسائی یہاں حاصل کی جا سکتی ہے۔

ہم کوکیز کا استعمال آپکو ہماری ویب سائٹ پر بہتریں تجربہ دینے کیلیے کرتے ہیں۔ مزید پڑھیے یا اپنی کوکی سیٹنگ تبدیل کیجیے۔

خطرے کی انتباہ: آپکا سرمایہ خطرے پر ہے۔ ہو سکتا ہے کہ لیورج پروڈکٹ سب کیلیے موزوں نہ ہوں۔ براہ کرم ہمارے مکمل رسک ڈسکلوژر کو پڑھیے۔